Preclinical study of recombinant adenovirus carrying p53, B7-1, and GM-CSF in the treatment of human laryngeal squamous carcinoma
- VernacularTitle:重组腺病毒介导多重基因对喉癌的治疗研究
- Author:
Lei LEI
;
Zhaohua QIU
;
La WANG
- Publication Type:Journal Article
- Keywords:
adenovirus;
tumor suppressor gene p53;
costimulatory factor B7 1;
granulocyte macrophage colony stimulating factor;
laryngeal neoplasms;
gene therapy
- From:
Medical Journal of Chinese People's Liberation Army
1981;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of a recombinant adenovirus carrying p53 gene, B7 1 gene and GM CSF (BB 102) on the nude mice transferred with laryngeal carcinoma. Methods Nude mice model bearing laryngocarcinoma was established using human laryngeal squamous carcinoma cell line (Hep 2). Large amounts of recombinant adenovirus (BB 102) were injected into the tumor. Changes in carcinoma treated with recombinant BB 102 adenovirus were observed under light and electron microscopes. Results The difference between experimental and control groups was statistically significant. The morphology of cells infected with BB 102 was analyzed for evidence of apoptosis by transmission electron microscopy. It has been shown that wild type P53 protein can inhibit cell growth and induce apoptosis, while B7 1 and GM CSF have no such effects. Conclusions The results showed that recombinant adenovirus BB 102 has significant efficacy in suppressing tumor cell growth and in inducing their apoptosis, suggesting that BB 102 might be developed into a therapeutic agent in clinical therapy of laryngeal carcinoma
